MX340756B - Compuestos de quinazolina como inhibidores de serina/treonina quinasa. - Google Patents

Compuestos de quinazolina como inhibidores de serina/treonina quinasa.

Info

Publication number
MX340756B
MX340756B MX2014001389A MX2014001389A MX340756B MX 340756 B MX340756 B MX 340756B MX 2014001389 A MX2014001389 A MX 2014001389A MX 2014001389 A MX2014001389 A MX 2014001389A MX 340756 B MX340756 B MX 340756B
Authority
MX
Mexico
Prior art keywords
serine
kinase inhibitors
threonine kinase
quinazoline compounds
compounds
Prior art date
Application number
MX2014001389A
Other languages
English (en)
Spanish (es)
Other versions
MX2014001389A (es
Inventor
F Blake James
M Wallace Eli
Chen Huifen
Joseph Chicarelli Mark
Demeese Jason
Ferdinand Garrey Rustam
Gaudino John
Gazzard Lewis
J Kaus Robert
Klintz Samuel
J Mohr Peter
a moreno David
Schwarz Jacob
S Siedem Christopher
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2014001389A publication Critical patent/MX2014001389A/es
Publication of MX340756B publication Critical patent/MX340756B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2014001389A 2011-08-04 2012-08-03 Compuestos de quinazolina como inhibidores de serina/treonina quinasa. MX340756B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515165P 2011-08-04 2011-08-04
PCT/US2012/049551 WO2013020062A1 (en) 2011-08-04 2012-08-03 Quinazoline compounds as serine/threonine kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2014001389A MX2014001389A (es) 2014-11-13
MX340756B true MX340756B (es) 2016-07-25

Family

ID=47003195

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001389A MX340756B (es) 2011-08-04 2012-08-03 Compuestos de quinazolina como inhibidores de serina/treonina quinasa.

Country Status (11)

Country Link
US (1) US9187462B2 (https=)
EP (1) EP2739618B1 (https=)
JP (1) JP6097289B2 (https=)
KR (1) KR101979042B1 (https=)
CN (1) CN103958502B (https=)
BR (1) BR112014002675A2 (https=)
CA (1) CA2844058A1 (https=)
ES (1) ES2552989T3 (https=)
MX (1) MX340756B (https=)
RU (1) RU2014108140A (https=)
WO (1) WO2013020062A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2681215B1 (en) 2011-02-28 2015-04-22 Array Biopharma, Inc. Serine/threonine kinase inhibitors
US9187462B2 (en) 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
DK2820009T3 (en) 2012-03-01 2018-04-16 Array Biopharma Inc Serine / threonine kinase inhibitors
TW201408658A (zh) * 2012-08-27 2014-03-01 Array Biopharma Inc 絲胺酸/酥胺酸激酶抑制劑
MX2015004615A (es) 2012-10-16 2015-07-17 Hoffmann La Roche Inhibidores de serina/treonina cinasa.
CN103254142B (zh) * 2013-04-26 2015-10-28 浙江工业大学 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
CN106029672B (zh) 2013-12-06 2019-03-29 基因泰克公司 丝氨酸/苏氨酸激酶抑制剂
JP6642942B2 (ja) 2013-12-30 2020-02-12 アレイ バイオファーマ、インコーポレイテッド セリン/トレオニンキナーゼ阻害剤
BR112016015235A2 (pt) 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
US11447493B2 (en) 2018-05-02 2022-09-20 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
EP3813819A4 (en) 2018-06-29 2022-08-17 Kinnate Biopharma Inc. CYCLIN-DEPENDENT KINASE INHIBITORS
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
BR112022007680A2 (pt) 2019-10-25 2022-08-09 Merck Sharp & Dohme Derivados de n-(heteroaril)quinazolin-2-amina como inibidores de lrrk2, composições farmacêuticas, e usos dos mesmos
CN115448864B (zh) * 2022-08-26 2023-12-22 上海方予健康医药科技有限公司 3-氟-3-(1-羟乙基)吡咯烷-1-羧酸叔丁酯的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
WO1995009851A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
EP0948496A2 (en) 1996-12-05 1999-10-13 Amgen inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
WO2001062233A2 (en) 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
AU5260601A (en) 2000-04-26 2001-11-07 Eisai Co Ltd Medicinal compositions promoting bowel movement
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
JP4606161B2 (ja) 2002-05-21 2011-01-05 アムジエン・インコーポレーテツド 置換複素環式化合物および使用方法
US7208498B2 (en) 2002-07-15 2007-04-24 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
AP2006003685A0 (en) * 2004-02-04 2006-08-31 Pfizer Prod Inc Substituted quinoline compounds
CA2561895A1 (en) 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyrimidines as potassium ion channel modulators
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
JP2008510766A (ja) 2004-08-27 2008-04-10 ゲーペーツェー ビオテック アーゲー ピリミジン誘導体
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
TW200716594A (en) 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Erkインヒビターとしてのピロリジン誘導体
CA2651072A1 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
CN101528729A (zh) 2006-08-23 2009-09-09 辉瑞产品公司 作为gsk-3抑制剂的嘧啶酮化合物
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
CN101568529A (zh) 2006-12-22 2009-10-28 诺瓦提斯公司 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物
JP5611826B2 (ja) 2007-09-04 2014-10-22 ザ スクリプス リサーチ インスティテュート タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン
AU2008324833A1 (en) 2007-11-06 2009-05-14 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic amines
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US9187426B2 (en) 2008-06-27 2015-11-17 Novartis Ag Organic compounds
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
ES2548882T3 (es) 2008-12-08 2015-10-21 Arena Pharmaceuticals, Inc. Moduladores del receptor de prostaciclina (PGl2) útiles para el tratamiento de trastornos relacionados con los mismos
EP2681215B1 (en) * 2011-02-28 2015-04-22 Array Biopharma, Inc. Serine/threonine kinase inhibitors
US9187462B2 (en) 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
DK2820009T3 (en) 2012-03-01 2018-04-16 Array Biopharma Inc Serine / threonine kinase inhibitors
TW201408658A (zh) 2012-08-27 2014-03-01 Array Biopharma Inc 絲胺酸/酥胺酸激酶抑制劑

Also Published As

Publication number Publication date
RU2014108140A (ru) 2015-09-10
HK1199021A1 (zh) 2015-06-19
WO2013020062A1 (en) 2013-02-07
CA2844058A1 (en) 2013-02-07
CN103958502A (zh) 2014-07-30
HK1199248A1 (zh) 2015-06-26
JP2014521696A (ja) 2014-08-28
US9187462B2 (en) 2015-11-17
US20150087664A1 (en) 2015-03-26
ES2552989T3 (es) 2015-12-03
MX2014001389A (es) 2014-11-13
BR112014002675A2 (pt) 2017-02-21
JP6097289B2 (ja) 2017-03-15
EP2739618A1 (en) 2014-06-11
KR101979042B1 (ko) 2019-05-15
CN103958502B (zh) 2016-02-10
KR20140062057A (ko) 2014-05-22
EP2739618B1 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
HK1210174A1 (en) Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
PH12014500373A1 (en) Amino quinazolines as kinase inhibitors
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX339873B (es) Inhibidores de serina/treonina cinasa.
AU2012250958A8 (en) Amino-pyridine-containing Spleen Tyrosine Kinase (Syk) inhibitors
MX2014002208A (es) Inhibidores de serina/treonina quinasa.
PH12016501071A1 (en) Serine/threonine kinase inhibitors
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
WO2013003298A3 (en) Inhibitors of pde10
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
MX2012008141A (es) Compuestos y metodos.
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
PH12014500814A1 (en) New aryl-quinoline derivatives
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
PH12015501038A1 (en) Inhibitors of iap
GEP201706687B (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
MX344429B (es) Nuevos compuestos de hexahidropirroloimidazolona.
MX338595B (es) Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus.
MX2014007398A (es) Derivado de 2,4-diamina-pirimidina como inhibidores de serina/treonina quinasa.

Legal Events

Date Code Title Description
FG Grant or registration